Health status measurement in COPD: the minimal clinically important difference of the clinical COPD questionnaire

J W H Kocks, M G Tuinenga, S M Uil, J W K van den Berg, E Ståhl, T van der Molen, J W H Kocks, M G Tuinenga, S M Uil, J W K van den Berg, E Ståhl, T van der Molen

Abstract

Background: Patient-reported outcomes (PRO) questionnaires are being increasingly used in COPD clinical studies. The challenge facing investigators is to determine what change is significant, ie what is the minimal clinically important difference (MCID). This study aimed to identify the MCID for the clinical COPD questionnaire (CCQ) in terms of patient referencing, criterion referencing, and by the standard error of measurement (SEM).

Methods: Patients were > or = 40 years of age, diagnosed with COPD, had a smoking history of >10 pack-years, and were participating in a randomized, controlled clinical trial comparing intravenous and oral prednisolone in patients admitted with an acute exacerbation of COPD. The CCQ was completed on Days 1-7 and 42. A Global Rating of Change (GRC) assessment was taken to establish the MCID by patient referencing. For criterion referencing, health events during a period of 1 year after Day 42 were included in this analysis.

Results: 210 patients were recruited, 168 completed the CCQ questionnaire on Day 42. The MCID of the CCQ total score, as indicated by patient referencing in terms of the GRC, was 0.44. The MCID of the CCQ in terms of criterion referencing for the major outcomes was 0.39, and calculation of the SEM resulted in a value of 0.21.

Conclusion: This investigation, which is the first to determine the MCID of a PRO questionnaire via more than one approach, indicates that the MCID of the CCQ total score is 0.4.

References

    1. Jones PW. Health status measurement in chronic obstructive pulmonary disease. Thorax. 2001;56:880–887. doi: 10.1136/thorax.56.11.880.
    1. Curtis JR, Patrick DL. The assessment of health status among patients with COPD. Eur Respir J Suppl. 2003;41:36s–45s. doi: 10.1183/09031936.03.00078102.
    1. Domingo-Salvany A, Lamarca R, Ferrer M, Garcia-Aymerich J, Alonso J, Felez M, Khalaf A, Marrades RM, Monso E, Serra-Batlles J, Anto JM. Health-related quality of life and mortality in male patients with chronic obstructive pulmonary disease. Am J Respir Crit Care Med. 2002;166:680–685. doi: 10.1164/rccm.2112043.
    1. Osman IM, Godden DJ, Friend JA, Legge JS, Douglas JG. Quality of life and hospital re-admission in patients with chronic obstructive pulmonary disease. Thorax. 1997;52:67–71.
    1. Guyatt GH, Berman LB, Townsend M, Pugsley SO, Chambers LW. A measure of quality of life for clinical trials in chronic lung disease. Thorax. 1987;42:773–778.
    1. Jones PW, Quirk FH, Baveystock CM. The St George's Respiratory Questionnaire. Respir Med. 1991;85 Suppl B:25–31.
    1. Ware JEJ, Sherbourne CD. The MOS 36-item short-form health survey (SF-36). I. Conceptual framework and item selection. Med Care. 1992;30:473–483.
    1. Hyland ME, Bott J, Singh S, Kenyon CA. Domains, constructs and the development of the breathing problems questionnaire. Qual Life Res. 1994;3:245–256. doi: 10.1007/BF00434898.
    1. Maille AR, Koning CJ, Zwinderman AH, Willems LN, Dijkman JH, Kaptein AA. The development of the 'Quality-of-life for Respiratory Illness Questionnaire (QOL-RIQ)': a disease-specific quality-of-life questionnaire for patients with mild to moderate chronic non-specific lung disease. Respir Med. 1997;91:297–309. doi: 10.1016/S0954-6111(97)90034-2.
    1. Molen van der T, Willemse BW, Schokker S, Ten Hacken NH, Postma DS, Juniper EF. Development, validity and responsiveness of the Clinical COPD Questionnaire. Health Qual Life Outcomes. 2003;1:13. doi: 10.1186/1477-7525-1-13.
    1. Beaton DE, Boers M, Wells GA. Many faces of the minimal clinically important difference (MCID): a literature review and directions for future research. Curr Opin Rheumatol. 2002;14:109–114. doi: 10.1097/00002281-200203000-00006.
    1. Jaeschke R, Singer J, Guyatt GH. Measurement of health status. Ascertaining the minimal clinically important difference. Control Clin Trials. 1989;10:407–415. doi: 10.1016/0197-2456(89)90005-6.
    1. Jones PW. Interpreting thresholds for a clinically significant change in health status in asthma and COPD. Eur Respir J. 2002;19:398–404. doi: 10.1183/09031936.02.00063702.
    1. Redelmeier DA, Guyatt GH, Goldstein RS. Assessing the minimal important difference in symptoms: a comparison of two techniques. J Clin Epidemiol. 1996;49:1215–1219. doi: 10.1016/S0895-4356(96)00206-5.
    1. Wyrwich KW, Tierney WM, Wolinsky FD. Further evidence supporting an SEM-based criterion for identifying meaningful intra-individual changes in health-related quality of life. J Clin Epidemiol. 1999;52:861–873. doi: 10.1016/S0895-4356(99)00071-2.
    1. Wyrwich KW. Minimal important difference thresholds and the standard error of measurement: is there a connection? J Biopharm Stat. 2004;14:97–110. doi: 10.1081/BIP-120028508.
    1. Celli BR, MacNee W, Agusti A, Anzueto A, Berg B, Buist AS, Calverley PMA, Chavannes N, Dillard T, Fahy B, Fein A, Heffner J, Lareau S, Meek P, Martinez F, McNicholas W, Muris J, Austegard E, Pauwels R, Rennard S, Rossi A, Siafakas N, Tiep B, Vestbo J, Wouters E, ZuWallack R. Standards for the diagnosis and treatment of patients with COPD: a summary of the ATS/ERS position paper. Eur Respir J. 2004;23:932–946.
    1. De Jong YP, Uil SM, Grotjohan HP, Postma DS, Kerstjens HAM, Van den Berg JWK. A comparison of intravenous versus oral administration of corticosteroids in the treatment of patients admitted to the hospital with an exacerbation of COPD. Eur Respir J. 2004;24(Suppl. 48):64s.
    1. Wyrwich KW, Wolinsky FD. Identifying meaningful intra-individual change standards for health-related quality of life measures. J Eval Clin Pract. 2000;6:39–49. doi: 10.1046/j.1365-2753.2000.00238.x.
    1. Pauwels RA, Buist AS, Calverley PM, Jenkins CR, Hurd SS, GOLD Scientific C. Global strategy for the diagnosis, management, and prevention of chronic obstructive pulmonary disease. NHLBI/WHO Global Initiative for Chronic Obstructive Lung Disease (GOLD) Workshop summary. American Journal Of Respiratory And Critical Care Medicine. 2001;163:1256–1276.
    1. Guyatt GH, Nogradi S, Halcrow S, Singer J, Sullivan MJ, Fallen EL. Development and testing of a new measure of health status for clinical trials in heart failure. J Gen Intern Med. 1989;4:101–107.
    1. Juniper EF, Guyatt GH, Willan A, Griffith LE. Determining a minimal important change in a disease-specific Quality of Life Questionnaire. J Clin Epidemiol. 1994;47:81–87. doi: 10.1016/0895-4356(94)90036-1.
    1. Jones PW. Quality of life, symptoms and pulmonary function in asthma: long-term treatment with nedocromil sodium examined in a controlled multicentre trial. Nedocromil Sodium Quality of Life Study Group. Eur Respir J. 1994;7:55–62. doi: 10.1183/09031936.94.07010055.
    1. Jones PW, Lasserson D. Relationship between change in St George's Respiratory Questionnaire score and patients' perception of treatment efficacy after one year of therapy with nedocromil sodium. Am Rev Respir Crit Care Med. 1994;149
    1. Jones PW, Bosh TK. Quality of life changes in COPD patients treated with salmeterol. Am J Respir Crit Care Med. 1997;155:1283–1289.
    1. Bestall JC, Paul EA, Garrod R, Garnham R, Jones PW, Wedzicha JA. Usefulness of the Medical Research Council (MRC) dyspnoea scale as a measure of disability in patients with chronic obstructive pulmonary disease. Thorax. 1999;54:581–586.

Source: PubMed

스폰서 및 공동 작업자

건강 상태

약물 개입

3
구독하다